Urinary N‐telopeptide levels in multiple myeloma patients, correlation with Tc‐99m‐sestaMIBI scintigraphy and other biochemical markers of disease activity

M. G. Alexandrakis; D. S. Kyriakou; F. H. Passam; N. Malliaraki; I. G. Vlachonikolis; N. Karkavitsas

doi:10.1002/hon.700

journal article Nov 29, 2002

Urinary N‐telopeptide levels in multiple myeloma patients, correlation with Tc‐99m‐sestaMIBI scintigraphy and other biochemical markers of disease activity

M. G. Alexandrakis D. S. Kyriakou F. H. Passam N. Malliaraki I. G. Vlachonikolis N. Karkavitsas

Hematological Oncology Vol. 21 No. 1 pp. 17-24 · Wiley

View at Publisher Save 10.1002/hon.700

Abstract

AbstractUrinary cross‐linked N‐telopeptide of type I collagen (NTx) has been reported to be a sensitive and specific marker of bone resorption in multiple myeloma (MM). In this study, we measured the levels of NTx in 30 newly diagnosed MM patients and 25 controls. We examined its association with the overall score of skeletal involvement measured by Tc‐99m‐MIBI scintigraphy and other biochemical markers of bone disease (tumour necrosis factor a (TNF‐a), serum calcium and creatinine). We further studied the correlation of NTx with the stage of disease (according to Durie–Salmon criteria) and bone marrow infiltration by plasma cells. High levels of NTx, bone marrow infiltration, TNF‐α, calcium and creatinine were noted at advanced stages of disease (p < 0.05). NTx and TNF‐a were found at significantly higher concentrations in patients with a high overall score (3 and 4) in Tc‐99m‐sestaMIBI in comparison to a low score (0, 1 and 2; p < 0.05). Positive correlations were found between NTx and TNF‐a, as well as between bone infiltration and TNF‐a or calcium. In conclusion, NTx is a useful marker for the monitoring of bone resorption in MM and correlates with imaging findings on Tc‐99m‐sestaMIBI and other biochemical markers of disease activity. Copyright © 2002 John Wiley & Sons, Ltd.

Topics

No keywords indexed for this article. Browse by subject →

References

27

[1]

10.1111/j.1365-2141.1995.tb05609.x

[2]

10.1007/s002770100302

[3]

10.1016/s0959-8049(97)10133-2

[4]

10.1034/j.1600-0609.2000.90074.x

[5]

Anderson KC "Role of cytokines in multiple myeloma" Semin Hematol (1999)

[6]

10.1016/s0301-472x(99)00061-2

[7]

Lichtenstein A "Production of cytokines by marrow cells obtained from patients with multiple myeloma" Blood (1989) 10.1182/blood.v74.4.1266.1266

[8]

10.1093/clinchem/41.10.1489

[9]

10.1111/j.1600-0609.1999.tb01906.x

[10]

Schneider DL "Urinary N‐telopeptide levels discriminate normal osteopenic and osteoporotic bone mineral density" Arch Intern Med (1997) 10.1001/archinte.1997.00440320149014

[11]

10.1002/jbmr.5650071119

[12]

A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival

Brian G. M. Durie, Sydney E. Salmon

Cancer 10.1002/1097-0142(197509)36:3<842::aid-cncr2820360303>3.0.co;2-u

[13]

10.1034/j.1600-0609.2000.065005331.x

[14]

10.1111/j.1365-2141.1995.tb05609.x

[15]

10.1111/j.1365-2141.1990.tb06330.x

[16]

10.1046/j.1365-2141.2000.01960.x

[17]

10.1002/jcb.240530405

[18]

10.1172/jci115106

[19]

10.3109/07357909709018921

[20]

10.1210/jc.77.3.824

[21]

10.1038/319516a0

[22]

Catalano L "Detection of focal myeloma lesions by technetium‐99m‐sestsMIBI scintigraphy" Haematologica (1999)

[23]

10.1007/s002590000440

[24]

10.1007/s002770100318

[25]

Chiu M "Effects of mitochondrial and plasma membrane potentials on accumulation of hexakis (2‐methoxyiso‐butylisonitril) technetium in cultured mouse fibroblasts" J Nucl Med (1990)

[26]

10.1046/j.1365-2141.1997.8672495.x

[27]

Witzig TE "Peripheral blood mononuclear plasma cells as a predictor of survival in patients with multiple myeloma" Blood (1996) 10.1182/blood.v88.5.1780.1780

Metrics

11

Citations

27

References

Details

Published: Nov 29, 2002
Vol/Issue: 21(1)
Pages: 17-24
License: View

Authors

Cite This Article

M. G. Alexandrakis, D. S. Kyriakou, F. H. Passam, et al. (2002). Urinary N‐telopeptide levels in multiple myeloma patients, correlation with Tc‐99m‐sestaMIBI scintigraphy and other biochemical markers of disease activity. Hematological Oncology, 21(1), 17-24. https://doi.org/10.1002/hon.700

Urinary N‐telopeptide levels in multiple myeloma patients, correlation with Tc‐99m‐sestaMIBI scintigraphy and other biochemical markers of disease activity

You May Also Like